MX2020013163A - Metodos para tratar trastornos linfoproliferativos malignos. - Google Patents
Metodos para tratar trastornos linfoproliferativos malignos.Info
- Publication number
- MX2020013163A MX2020013163A MX2020013163A MX2020013163A MX2020013163A MX 2020013163 A MX2020013163 A MX 2020013163A MX 2020013163 A MX2020013163 A MX 2020013163A MX 2020013163 A MX2020013163 A MX 2020013163A MX 2020013163 A MX2020013163 A MX 2020013163A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treating malignant
- lymphoproliferative disorders
- malignant lymphoproliferative
- disorders
- Prior art date
Links
- 230000003211 malignant effect Effects 0.000 title abstract 3
- 208000030289 Lymphoproliferative disease Diseases 0.000 title 1
- FARXPFGGGGLENU-UHFFFAOYSA-N 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione Chemical compound C12=CC=3OCOC=3C=C2N(C)C=C1C1=C(C=2C3=CC(F)=CC=C3OC=2)C(=O)NC1=O FARXPFGGGGLENU-UHFFFAOYSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan métodos para tratar trastornos linfoproliferativos malignos en un paciente, que comprende administrar una cantidad efectiva de un inhibidor de GSK-3ß, por ejemplo 9-ING-41. También se proporcionan métodos para tratar trastornos linfoproliferativos malignos que comprende administrar un inhibidor GSK-3ß, por ejemplo 9-ING-41, en combinación con un segundo o múltiples agentes terapéuticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862680739P | 2018-06-05 | 2018-06-05 | |
PCT/US2019/035576 WO2019236703A1 (en) | 2018-06-05 | 2019-06-05 | Methods of treating malignant lymphoproliferative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020013163A true MX2020013163A (es) | 2021-02-18 |
Family
ID=68769443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013163A MX2020013163A (es) | 2018-06-05 | 2019-06-05 | Metodos para tratar trastornos linfoproliferativos malignos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11510904B2 (es) |
EP (1) | EP3801768A4 (es) |
JP (1) | JP2021527039A (es) |
KR (1) | KR20210045364A (es) |
CN (2) | CN117883438A (es) |
AU (1) | AU2019280693A1 (es) |
BR (1) | BR112020024931A2 (es) |
CA (1) | CA3102555A1 (es) |
IL (1) | IL279155A (es) |
MX (1) | MX2020013163A (es) |
WO (1) | WO2019236703A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020013163A (es) * | 2018-06-05 | 2021-02-18 | Actuate Therapeutics Inc | Metodos para tratar trastornos linfoproliferativos malignos. |
AU2020415440A1 (en) * | 2019-12-26 | 2022-08-04 | Actuate Therapeutics, Inc. | Compounds for the treatment of myelofibrosis |
WO2022109057A1 (en) * | 2020-11-17 | 2022-05-27 | Brown University | Inhibition of glycogen synthase kinase-3 (gsk-3) |
CN113684180B (zh) * | 2021-08-31 | 2023-05-26 | 山东大学第二医院 | 一种提高骨髓瘤杀伤活性的nk细胞制备方法 |
WO2023172629A2 (en) * | 2022-03-08 | 2023-09-14 | Brown University | Anticancer maleimide derivatives for use with immune checkpoint blockade |
WO2024006750A1 (en) * | 2022-06-27 | 2024-01-04 | Actuate Therapeutics, Inc. | Oral dosage forms of elraglusib |
WO2024028433A1 (en) * | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2446269T3 (es) | 2006-12-19 | 2014-03-06 | The Board Of Trustees Of The University Of Illinois | 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos |
BR112014018655B1 (pt) | 2012-02-21 | 2022-02-08 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A | Composto de 1h-indazol-3-carboxamida, e, composição farmacêutica |
SI2909204T1 (sl) | 2012-10-12 | 2019-06-28 | The Broad Institute, Inc. | Inhibitorji GSK3 in postopki njihove uporabe |
US20160375006A1 (en) * | 2012-10-12 | 2016-12-29 | The Broad Institute, Inc. | Uses of paralog-selective inhibitors of gsk3 kinases |
WO2014165851A1 (en) | 2013-04-05 | 2014-10-09 | The Children's Hospital Of Philadelphia | Transient up-regulation of myc in b-cell lymphomas |
WO2015155738A2 (en) * | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
JP6534098B2 (ja) * | 2014-09-12 | 2019-06-26 | 国立大学法人 鹿児島大学 | 成人t細胞白血病治療薬 |
MX2020013163A (es) * | 2018-06-05 | 2021-02-18 | Actuate Therapeutics Inc | Metodos para tratar trastornos linfoproliferativos malignos. |
-
2019
- 2019-06-05 MX MX2020013163A patent/MX2020013163A/es unknown
- 2019-06-05 US US15/734,699 patent/US11510904B2/en active Active
- 2019-06-05 KR KR1020207037918A patent/KR20210045364A/ko unknown
- 2019-06-05 CN CN202311356900.5A patent/CN117883438A/zh active Pending
- 2019-06-05 CA CA3102555A patent/CA3102555A1/en active Pending
- 2019-06-05 BR BR112020024931-9A patent/BR112020024931A2/pt unknown
- 2019-06-05 CN CN201980037210.9A patent/CN112351819B/zh active Active
- 2019-06-05 WO PCT/US2019/035576 patent/WO2019236703A1/en unknown
- 2019-06-05 JP JP2020567578A patent/JP2021527039A/ja active Pending
- 2019-06-05 AU AU2019280693A patent/AU2019280693A1/en active Pending
- 2019-06-05 EP EP19815715.8A patent/EP3801768A4/en active Pending
-
2020
- 2020-12-02 IL IL279155A patent/IL279155A/en unknown
-
2022
- 2022-11-03 US US18/052,369 patent/US11980607B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20210228546A1 (en) | 2021-07-29 |
IL279155A (en) | 2021-01-31 |
US20230126700A1 (en) | 2023-04-27 |
JP2021527039A (ja) | 2021-10-11 |
CN112351819B (zh) | 2023-11-10 |
US11980607B2 (en) | 2024-05-14 |
EP3801768A4 (en) | 2022-04-20 |
CN117883438A (zh) | 2024-04-16 |
BR112020024931A2 (pt) | 2021-03-09 |
EP3801768A1 (en) | 2021-04-14 |
AU2019280693A1 (en) | 2020-12-03 |
WO2019236703A1 (en) | 2019-12-12 |
US11510904B2 (en) | 2022-11-29 |
KR20210045364A (ko) | 2021-04-26 |
CA3102555A1 (en) | 2019-12-12 |
CN112351819A (zh) | 2021-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020013163A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
MX2022010270A (es) | Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion. | |
MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
MX2017012123A (es) | Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer. | |
MX2020001727A (es) | Terapia de combinacion. | |
AU2019310335A8 (en) | Methods of treating cancer with PI3K inhibitor, GDC-0077 | |
MX2020011817A (es) | Metodos para tratar el linfoma. | |
MX2019013862A (es) | Terapia de combinacion. | |
MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
MX2021014905A (es) | Células seguras e invisibles para el sistema inmunitario. | |
BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. | |
CL2022000790A1 (es) | Método para tratar vih con cabotegravir y rilpivirina | |
MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
PH12021551138A1 (en) | Application of chidamide in combination with r-chop, and drug combination | |
MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |